All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Human Methylenetetrahydrofolate Reductase (MTHFR) gene is located at chromosome 1p36.3 and contains 11 exons \[[@pone.0154337.ref001], [@pone.0154337.ref002]\]. As a kind of folate-metabolizing enzyme, MTHFR protein is essential for the methylation of homocysteine (Hcy) to methionine, through catalyzing the irreversible reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate \[[@pone.0154337.ref003]--[@pone.0154337.ref006]\]. The abnormity of MTHFR structure or function can take part in the occurrence of Hyperhomocysteinemia \[[@pone.0154337.ref005]--[@pone.0154337.ref007]\]. Two polymorphic variants, including C677T (rs1801133) and A1298C (rs1801131), have been identified in MTHFR gene \[[@pone.0154337.ref008]--[@pone.0154337.ref011]\].

Non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disease, is the hepatic manifestation of the metabolic syndrome without a history of excess alcohol consumption \[[@pone.0154337.ref012]--[@pone.0154337.ref014]\]. The hepatic pathology of NAFLD mainly consists of simple fatty liver, non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis \[[@pone.0154337.ref015]--[@pone.0154337.ref018]\]. And NASH was characterized by hepatocellular injury and inflammation \[[@pone.0154337.ref015]--[@pone.0154337.ref018]\]. The polymorphisms of several genes, such as Patatin-like phospholipase domain-containing 3 (PNPLA3), leptin receptor (LEPR) and MTHFR, were reported to be involved in the genetic susceptibility to NAFLD \[[@pone.0154337.ref019]--[@pone.0154337.ref021]\]. For MTHFR gene, conflicting results regarding its potential correlation with NAFLD were reported \[[@pone.0154337.ref022]--[@pone.0154337.ref030]\]. Here, we focus on the polymorphisms of human MTHFR and assessed its genetic association with NAFLD risks via a meta-analysis, a very powerful tool for integrating and analyzing the conflicting data from different studies \[[@pone.0154337.ref031]\].

To our knowledge, no meta-analysis on the association of MTHFR genetic variants and overall NAFLD risks has been reported. Hence, we first carried out a meta-analysis to investigate the relationship between MTHFR polymorphisms (C677T and A1298C) and susceptibility to NAFLD. Our finding showed that both C677T and A1298C polymorphisms of MTHFR gene might positively correlate to the risks of NAFLD.

Methods {#sec006}
=======

Searching strategy {#sec007}
------------------

A computerized literature search was performed from the electronic databases, including PubMed, Excerpta Medica Database (EMBASE), Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science (WOS), China National Knowledge Infrastructure (CNKI)/WANFANG, Scopus and EBSCOhost in April 1^st^, 2016. There was no language or region restriction. The combinations of following keywords were used: "Methylenetetrahydrofolate Reductase (NADPH)" or "Methylene-THF Reductase (NADPH)" or "MTHFR" or "Methylenetetra hydrofolate Reductase"; "Non-alcoholic Fatty Liver Disease" or "NAFLD" or "Fatty Liver, Nonalcoholic" or "Livers, Nonalcoholic Fatty" or "Nonalcoholic Fatty Livers" or "Nonalcoholic Steatohepatitis" or "Nonalcoholic Steatohepatitides" or "Steatohepatitides, Nonalcoholic" or "Steatohepatitis, Nonalcoholic"; "Polymorphism, Genetic" or "Genetic Polymorphisms" or "Genetic Polymorphism" or "Polymorphism (Genetics)" or "Polymorphisms, Genetic". The full details of databases searching terms were also provided ([S1 Text](#pone.0154337.s003){ref-type="supplementary-material"}).

Inclusion and exclusion criteria {#sec008}
--------------------------------

The eligible case-control studies were identified according to the following inclusion and exclusion criteria. Inclusion criteria: 1) The data on the association between MTHFR polymorphisms and susceptibility to NAFLD was provided; 2) The individual genotype frequencies for MTHFR polymorphisms could be extracted. Exclusion criteria: 1) duplicated studies; 2) reviews or books; 3) non-clinical data; 4) other genes; 5) non-NAFLD diseases; 6) case, trial, or non-polymorphism; 7) meeting/conference abstracts; 8) unavailable data.

Data extraction strategy {#sec009}
------------------------

Data was extracted from qualified articles independently by the authors (MYS LZ SLS JNL) using the same reporting form. The controversial evaluations were resolved through discussion. If the data was unavailable, an attempt was made to contact corresponding author to request missing data via E-mail. The following information was extracted: mutation site, first author, year of publication, country, ethnicity, sample sizes in case and control group, source of control, genotyping method, gender and age in case group, disease group, allele and genotype frequencies in each group, The Χ^2^ and *P* value of Hardy-Weinberg Equilibrium (HWE) test in control group. HWE value was calculated by chi-squared test and *P* value less than 0.05 was considered a departure from HWE.

Statistical analysis {#sec010}
--------------------

The *P* value, odd radio (OR) and corresponding 95% confidence interval (CI) were calculated by Mantel-Haenszel statistics under the allele, homozygote, heterozygote, dominant or recessive models. *P* value \<0.05 was considered statistically significant association between C677T and A1298C polymorphisms of MTHFR and NAFLD risks. Χ^2^-based Q statistic and I^2^ test were applied to analyze the overall heterogeneities. When I^2^ values \< 25% or *P* value of heterogeneity \>0.10, a fixed-effect model was selected for Mantel-Haenszel statistics. Otherwise, a random-effect model was used \[[@pone.0154337.ref032]--[@pone.0154337.ref035]\]. When significant heterogeneity existed, sensitivity analysis was also performed to analyze the study that influenced homogeneity of the included studies. The potential publication bias was evaluated by Begg's funnel plot with pseudo 95% confidence limits \[[@pone.0154337.ref036]\]. Statistical analyses were conducted by Review Manager Version 5.0 (The Nordic Cochrane Centre, The Cochrane Collaboration, Denmark) and Stata/SE 12.0 (StataCorp, College Station, USA) software.

Results {#sec011}
=======

Study inclusion and characteristics {#sec012}
-----------------------------------

We searched the on-line electronic databases, including PubMed, EMBASE, CENTRAL, WOS, CNKI/WANFANG, Scopus and EBSCOhost (updated to April 1^st^, 2016), to obtain the eligible case-control studies. Flow chart of studies selection in meta-analysis was shown in [Fig 1](#pone.0154337.g001){ref-type="fig"}.

![Flow chart of eligible studies selection during meta-analysis.](pone.0154337.g001){#pone.0154337.g001}

Possibly relevant articles of 221 were obtained from the electronic databases, including PubMed (n = 10), EMBASE (n = 29), CENTRAL (n = 0), WOS (n = 24), CNKI/WANFANG (n = 3), Scopus (n = 144) and EBSCOhost (n = 11). After 50 duplicated articles were removed, the 153 articles were excluded by screening the title and abstract: 59 articles are reviews or books; 11 articles do not provide the clinical data; 16 articles are related to the other genes; 46 articles focus on non-NAFLD diseases; 21 articles are case, trial or fail to contain the data of gene polymorphism. 18 potentially articles were then assessed for eligibility. The data was extracted from all these full-text articles. As shown in [S2 Text](#pone.0154337.s004){ref-type="supplementary-material"}, 6 articles were meeting/conference abstracts and 4 articles were lack of usable data. We failed to obtain missing data. Finally, 8 articles (785 cases and 1188 controls) fulfilled the inclusion criteria and were included in the present meta-analysis \[[@pone.0154337.ref023]--[@pone.0154337.ref030]\]. The data was extracted independently by the authors (MYS LZ SLS JNL). The characteristics of included articles were summarized and showed in [Table 1](#pone.0154337.t001){ref-type="table"}. All the case-control studies were population-based. This meta-analysis was carried out according to the recommendations of the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" (PRISMA) statement ([S1 Table](#pone.0154337.s001){ref-type="supplementary-material"}) and "Meta-analysis on Genetic Association Studies" statement ([S2 Table](#pone.0154337.s002){ref-type="supplementary-material"}) \[[@pone.0154337.ref037]\].

10.1371/journal.pone.0154337.t001

###### Characteristics of eligible studies in meta-analysis.

![](pone.0154337.t001){#pone.0154337.t001g}

  first author         year   country   ethnicity   sample sizes   source of control   genotying method   case                                    
  -------------------- ------ --------- ----------- -------------- ------------------- ------------------ -------------------------------- ------ ---------
  Chen et al.          2014   China     Asian       212            175                 PB                 PCR-gene CHIP                    60.8   40\~54
  de Carvalho et al.   2013   Brazil    Caucasian   35             45                  PB                 PCR-RFLP/PCR-ASA                 25.7   mean 49
  Franco et al.        2013   Brazil    Caucasian   134            134                 PB                 PCR-RFLP                         42.5   32\~56
  Hu et al.            2009   China     Asian       63             52                  PB                 PCR-RFLP                         NA     NA
  Kasapoglu et al.     2015   Turkey    Caucasian   150            136                 PB                 PCR-SSCP                         30.0   32\~63
  Orlovskiy et al.     2015   Ukraine   Caucasian   100            40                  PB                 PCR-fluorescence hybridization   NA     NA
  Sazci et al.         2008   Turkey    Caucasian   57             324                 PB                 PCR-RFLP                         54.4   18\~66
  Serin et al.         2007   Turkey    Caucasian   34             282                 PB                 PCR-RFLP                         55.9   33\~51

PB: population-based; NA: not available; PCR-RFLP: polymerase chain reaction--restriction fragment length polymorphism; PCR-ASA: polymerase chain reaction--amplicon sequence analysis; PCR-SSCP: Polymerase chain reaction-single strand conformation polymorphism.

Meta-analysis on the association between NAFLD risks and C677T polymorphism of MTHFR {#sec013}
------------------------------------------------------------------------------------

Next, the genetic association between MTHFR C677T polymorphism and susceptibility to NAFLD was measured. As shown in [Fig 2A](#pone.0154337.g002){ref-type="fig"}, the result (I^2^ = 56% and *P* = 0.004) revealed that high heterogeneity among studies was detected for C677T polymorphism. Random-effect model was thus applied for meta-analysis. The data on the association between C677T allele frequency of MTHFR and susceptibility to NAFLD was obtained (T vs C, OR = 1.20, 95% CI = 0.98\~1.47, *P* = 0.07). In addition, the potential publication bias was evaluated by Begg's funnel plot with pseudo 95% confidence limits. The result of [Fig 2B](#pone.0154337.g002){ref-type="fig"} suggested that basically symmetric plot (z = 0.14, *P* = 0.893) excludes the presence of large publication bias.

![Meta analysis for the association between C677T allele frequency of MTHFR and the risks of NAFLD.\
(A) Forest plot under T vs C model; (B) Begg's funnel plot of publication biases under T vs C model.](pone.0154337.g002){#pone.0154337.g002}

The contrast of the homozygote model (T/T vs C/C), heterozygote model (C/T vs C/C), dominant model (C/T+T/T vs C/C) and recessive model (T/T vs C/C+C/T) was then detected respectively, through the meta-analysis, in that the data on genotype frequencies of MTHFR C677T polymorphism was available. Genotype distribution and characteristics of MTHFR C677T polymorphism in different case-control studies were shown in [Table 2](#pone.0154337.t002){ref-type="table"}. The T/T vs C/C (I^2^ = 47% and *P* = 0.02), C/T+T/T vs C/C (I^2^ = 45% and *P* = 0.03) and T/T vs C/C+C/T (I^2^ = 26% and *P* = 0.16) data indicated the existence of the moderate degree of heterogeneity across studies ([Table 3](#pone.0154337.t003){ref-type="table"}). A random-effect model was thus used. However, fixed-effect model was used for the C/T vs C/C model (I^2^ = 21% and *P* = 0.21). Pooled analysis for the association between C677T genotype frequencies and the risks of NAFLD was shown in [Table 3](#pone.0154337.t003){ref-type="table"}. Briefly, compared with control group, an increased NAFLD risk was observed in case group under homozygote model (T/T vs C/C, OR = 1.49, 95% CI = 1.03\~2.15, *P* = 0.04) and recessive model (T/T vs C/C+C/T, OR = 1.42, 95% CI = 1.07\~1.88, *P* = 0.02), but not the other genetics models (C/T vs C/C, OR = 1.14, 95% CI = 0.93\~1.39, *P* = 0.21; C/T+T/T vs C/C, OR = 1.18, 95% CI = 0.91\~1.52, *P* = 0.21). In addition, the results of HWE test ([Table 2](#pone.0154337.t002){ref-type="table"}) in control group of two studies \[[@pone.0154337.ref024], [@pone.0154337.ref025]\] indicated that the genotype distributions deviated from HWE (Χ^2^ = 5.605, *P* = 0.018; Χ^2^ = 190.839, *P*\<0.05). The subgroup analyses under all genetic models were also performed based on ethnicity or HWE ([Table 4](#pone.0154337.t004){ref-type="table"}) via Stata/SE 12.0 software. A significantly increased NAFLD risk was observed in Asian population (T vs C, OR = 1.58, 95% CI = 1.13\~2.20, *P* = 0.007; T/T vs C/C, OR = 1.97, 95% CI = 1.15\~3.37, *P* = 0.014; C/T vs C/C, OR = 1.72, 95% CI = 1.16\~2.55, *P* = 0.007; C/T+T/T vs C/C, OR = 1.81, 95% CI = 1.26\~2.59, *P* = 0.001) and HWE *P*\>0.05 subgroup (T vs C, OR = 1.31, 95% CI = 1.03\~1.67, *P* = 0.030; T/T vs C/C, OR = 1.85, 95% CI = 1.15\~2.97, *P* = 0.011; T/T vs C/C+C/T, OR = 1.72, 95% CI = 1.21\~2.46, *P* = 0.003). In order to evaluate the influence of each study on the overall OR under all genetic models, the sensitivity meta-analyses, in which one study is omitted at a time, were also performed. As shown in [Fig 3](#pone.0154337.g003){ref-type="fig"}, the results indicated that the corresponding pooled OR value did not differ significantly from that of the overall meta-analysis. Furthermore, no significant publication bias was observed in all above genetic models via Begg's funnel plot and Egger's test (Data not shown), suggesting these results are reliable. These data indicated that the T/T genotype of MTHFR C677T polymorphism seems to be associated with genetic susceptibility to NAFLD, especially in Asian population.

![The sensitivity meta-analyses for the association between C677T polymorphism of MTHFR and the risks of NAFLD.](pone.0154337.g003){#pone.0154337.g003}

10.1371/journal.pone.0154337.t002

###### Genotype distribution of MTHFR C677T and A1298C polymorphisms.

![](pone.0154337.t002){#pone.0154337.t002g}

  site         first author   year   group               case   control   HWE                                           
  ------------ -------------- ------ ------------------- ------ --------- ----- ----- ----- ----- ----- ----- --------- ------------
  **C677T**    de Carvalho    2013   \-                  12     17        6     35    23    20    2     45    0.837     0.360
               Franco         2013   \-                  57     57        20    134   50    67    17    134   0.559     0.455
               Chen           2014   \-                  71     101       40    212   82    65    28    175   5.605     **0.018**
               Kasapoglu      2015   C677T-stage 1       12     34        16    62    40    56    12    108   1.349     0.245
                                     C677T-stage 2       4      12        8     24    40    56    12    108             
                                     C677T-stage 3       3      8         5     16    40    56    12    108             
               Hu             2009   \-                  21     20        22    63    26    17    9     52    3.732     0.053
               Orlovskiy      2015   C677T-NAFLD-all     46     38        16    100   20    14    6     40    1.637     0.201
                                     C677T-NAFLD-only    25     23        5     53    20    14    6     40              
                                     C677T-NAFLD-T2D     21     15        11    47    20    14    6     40              
               Sazci          2008   NASH-overall        32     21        4     57    161   139   24    324   0.651     0.420
                                     NASH-men            19     10        2     31    81    75    15    171   0.162     0.688
                                     NASH-women          13     11        2     26    80    64    9     153   0.671     0.413
               Serin          2007   NAFLD               19     1         14    34    131   25    126   282   190.839   **\<0.05**
                                     NAFL                8      0         4     12    131   25    126   282             
                                     NASH                11     1         10    22    131   25    126   282             
  **A1298C**   de Carvalho    2013   \-                  20     15        0     35    26    17    2     45    0.141     0.708
               Franco         2013   \-                  74     53        7     134   65    63    6     134   3.711     0.054
               Kasapoglu      2015   A1298C-stage 1      12     18        8     38    40    24    4     68    0.025     0.874
                                     A1298C-stage 2      4      8         6     18    40    24    4     68              
                                     A1298C-stage 3      3      5         3     11    40    24    4     68              
               Orlovskiy      2015   A1298C-NAFLD-all    53     34        13    100   20    17    3     40    0.056     0.813
                                     A1298C-NAFLD-only   32     17        4     53    20    17    3     40              
                                     A1298C-NAFLD-T2D    22     16        9     47    20    17    3     40              
               Sazci          2008   NASH-all            13     34        10    57    137   154   33    324   1.159     0.282
                                     NASH-men            7      20        4     31    73    79    19    171   0.119     0.731
                                     NASH-women          6      14        6     26    64    75    14    153   1.458     0.227

NA: not available; HWE: Hardy-Weinberg Equilibrium.

10.1371/journal.pone.0154337.t003

###### Pooled analysis for the association between MTHFR C677T genotype frequencies and the risks of NAFLD.

![](pone.0154337.t003){#pone.0154337.t003g}

  Comparison                       study              case          control   Test of association   Heterogeneity   Model                                                    
  -------------------------------- ------------------ ------------- --------- --------------------- --------------- ------------------------- ---------- -------- ---------- -------
  **T/T vs C/C (homozygote)**                         **T/T**                 **T/T**                               **1.49 \[1.03, 2.15\]**   **0.04**   **47**   **0.02**   **R**
                                   de Carvalho,2013   6             18        2                     25              5.75 \[1.00, 32.95\]                                     
                                   Franco,2013        20            77        17                    67              1.03 \[0.49, 2.18\]                                      
                                   Chen,2014          40            111       28                    110             1.65 \[0.93, 2.94\]                                      
                                   Kasapoglu,2015     16            28        12                    52              4.44 \[1.65, 11.94\]                                     
                                                      8             12        12                    52              6.67 \[1.71, 26.04\]                                     
                                                      5             8         12                    52              5.56 \[1.16, 26.70\]                                     
                                   Hu,2009            22            43        9                     35              3.03 \[1.15, 7.95\]                                      
                                   Orlovskiy,2015     16            62        6                     26              1.16 \[0.40, 3.40\]                                      
                                                      5             30        6                     26              0.67 \[0.18, 2.51\]                                      
                                                      11            32        6                     26              1.75 \[0.54, 5.62\]                                      
                                   Sazci,2008         4             36        24                    185             0.84 \[0.27, 2.58\]                                      
                                                      2             21        15                    96              0.57 \[0.12, 2.70\]                                      
                                                      2             15        9                     89              1.37 \[0.27, 7.05\]                                      
                                   Serin,2007         14            33        126                   257             0.77 \[0.37, 1.59\]                                      
                                                      4             12        126                   257             0.52 \[0.15, 1.77\]                                      
                                                      10            21        126                   257             0.95 \[0.39, 2.30\]                                      
  **C/T vs C/C (heterozygote)**                       **C/T**                 **C/T**                               **1.14 \[0.93, 1.39\]**   **0.21**   **21**   **0.21**   **F**
                                   de Carvalho,2013   17            29        20                    43              1.63 \[0.63, 4.22\]                                      
                                   Franco,2013        57            114       67                    117             0.75 \[0.44, 1.25\]                                      
                                   Chen,2014          101           172       65                    147             1.79 \[1.15, 2.80\]                                      
                                   Kasapoglu,2015     34            46        56                    96              2.02 \[0.93, 4.38\]                                      
                                                      12            16        56                    96              2.14 \[0.64, 7.13\]                                      
                                                      8             11        56                    96              1.90 \[0.48, 7.63\]                                      
                                   Hu,2009            20            41        17                    43              1.46 \[0.61, 3.46\]                                      
                                   Orlovskiy,2015     38            84        14                    34              1.18 \[0.53, 2.64\]                                      
                                                      23            48        14                    34              1.31 \[0.54, 3.19\]                                      
                                                      15            36        14                    34              1.02 \[0.39, 2.64\]                                      
                                   Sazci,2008         21            53        139                   300             0.76 \[0.42, 1.38\]                                      
                                                      10            29        75                    156             0.57 \[0.25, 1.30\]                                      
                                                      11            24        64                    144             1.06 \[0.44, 2.52\]                                      
                                   Serin,2007         1             20        25                    156             0.28 \[0.04, 2.15\]                                      
                                                      0             8         25                    156             0.30 \[0.02, 5.42\]                                      
                                                      1             12        25                    156             0.48 \[0.06, 3.86\]                                      
  **C/T+T/T vs C/C (dominant)**                       **C/T+T/T**             **C/T+T/T**                           **1.18 \[0.91, 1.52\]**   **0.21**   **45**   **0.03**   **R**
                                   de Carvalho,2013   23            35        22                    45              2.00 \[0.81, 4.98\]                                      
                                   Franco,2013        77            134       84                    134             0.80 \[0.49, 1.31\]                                      
                                   Chen,2014          141           212       93                    175             1.75 \[1.16, 2.64\]                                      
                                   Kasapoglu,2015     50            62        68                    108             2.45 \[1.17, 5.14\]                                      
                                                      20            24        68                    108             2.94 \[0.94, 9.22\]                                      
                                                      13            16        68                    108             2.55 \[0.68, 9.49\]                                      
                                   Hu,2009            42            63        26                    52              2.00 \[0.94, 4.25\]                                      
                                   Orlovskiy,2015     54            100       20                    40              1.17 \[0.56, 2.45\]                                      
                                                      28            53        20                    40              1.12 \[0.49, 2.55\]                                      
                                                      26            47        20                    40              1.24 \[0.53, 2.88\]                                      
                                   Sazci,2008         25            57        163                   324             0.77 \[0.44, 1.36\]                                      
                                                      12            31        90                    171             0.57 \[0.26, 1.24\]                                      
                                                      13            26        73                    153             1.10 \[0.48, 2.52\]                                      
                                   Serin,2007         15            34        151                   282             0.68 \[0.33, 1.40\]                                      
                                                      4             12        151                   282             0.43 \[0.13, 1.47\]                                      
                                                      11            22        151                   282             0.87 \[0.36, 2.07\]                                      
  **T/T vs C/C+C/T (recessive)**                      **T/T**                 **T/T**                               **1.42 \[1.07, 1.88\]**   **0.02**   **26**   **0.16**   **R**
                                   de Carvalho,2013   6             35        2                     45              4.45 \[0.84, 23.59\]                                     
                                   Franco,2013        20            134       17                    134             1.21 \[0.60, 2.42\]                                      
                                   Chen,2014          40            212       28                    175             1.22 \[0.72, 2.08\]                                      
                                   Kasapoglu,2015     16            62        12                    108             2.78 \[1.22, 6.36\]                                      
                                                      8             24        12                    108             4.00 \[1.41, 11.31\]                                     
                                                      5             16        12                    108             3.64 \[1.08, 12.26\]                                     
                                   Hu,2009            22            63        9                     52              2.56 \[1.06, 6.22\]                                      
                                   Orlovskiy,2015     16            100       6                     40              1.08 \[0.39, 2.99\]                                      
                                                      5             53        6                     40              0.59 \[0.17, 2.09\]                                      
                                                      11            47        6                     40              1.73 \[0.58, 5.20\]                                      
                                   Sazci,2008         4             57        24                    324             0.94 \[0.31, 2.83\]                                      
                                                      2             31        15                    171             0.72 \[0.16, 3.30\]                                      
                                                      2             26        9                     153             1.33 \[0.27, 6.55\]                                      
                                   Serin,2007         14            34        126                   282             0.87 \[0.42, 1.78\]                                      
                                                      4             12        126                   282             0.62 \[0.18, 2.10\]                                      
                                                      10            22        126                   282             1.03 \[0.43, 2.47\]                                      

R: Random-effect; F:Fixed-effect.

10.1371/journal.pone.0154337.t004

###### Subgroup analysis for the association between MTHFR C677T genotype frequencies and the risks of NAFLD.
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  Comparison                       subgroup        Number of studies   Sample size   OR (95% CI)   *P* value             
  -------------------------------- --------------- ------------------- ------------- ------------- --------------------- -----------
  **T vs C (allele)**              **Ethnicity**                                                                         
                                   Asian           2                   275           227           1.58 \[1.13, 2.20\]   **0.007**
                                   Caucasian       14                  653           2117          1.14 \[0.91, 1.42\]   0.269
                                   **HWE**                                                                               
                                   *P*\<0.05       4                   280           1021          0.94 \[0.62, 1.44\]   0.778
                                   *P*\>0.05       12                  648           1323          1.31 \[1.03, 1.67\]   **0.030**
  **T/T vs C/C (homozygote)**      **Ethnicity**                                                                         
                                   Asian           2                   275           227           1.97 \[1.15, 3.37\]   **0.014**
                                   Caucasian       14                  653           2117          1.39 \[0.90, 2.13\]   0.134
                                   **HWE**                                                                               
                                   *P*\<0.05       4                   280           1021          1.01 \[0.63, 1.64\]   0.954
                                   *P*\>0.05       12                  648           1323          1.85 \[1.15, 2.97\]   **0.011**
  **C/T vs C/C (heterozygote)**    **Ethnicity**                                                                         
                                   Asian           2                   275           227           1.72 \[1.16, 2.55\]   **0.007**
                                   Caucasian       14                  653           2117          0.99 \[0.78, 1.24\]   0.914
                                   **HWE**                                                                               
                                   *P*\<0.05       4                   280           1021          1.39 \[0.93, 2.07\]   0.108
                                   *P*\>0.05       12                  648           1323          1.07 \[0.85, 1.34\]   0.581
  **C/T+T/T vs C/C (dominant)**    **Ethnicity**                                                                         
                                   Asian           2                   275           227           1.81 \[1.26, 2.59\]   **0.001**
                                   Caucasian       14                  653           2117          1.07 \[0.82, 1.39\]   0.635
                                   **HWE**                                                                               0.211
                                   *P*\<0.05       4                   280           1021          0.93 \[0.49, 1.75\]   0.814
                                   *P*\>0.05       12                  648           1323          1.25 \[0.93, 1.67\]   0.138
  **T/T vs C/C+C/T (recessive)**   **Ethnicity**                                                                         
                                   Asian           2                   275           227           1.62 \[0.80, 3.28\]   0.181
                                   Caucasian       14                  653           2117          1.38 \[0.99, 1.92\]   0.060
                                   **HWE**                                                                               
                                   *P*\<0.05       4                   280           1021          1.02 \[0.71, 1.47\]   0.912
                                   *P*\>0.05       12                  648           1323          1.72 \[1.21, 2.46\]   **0.003**

HWE: Hardy-Weinberg Equilibrium.

Meta-analysis on the association between NAFLD risks and A1298C polymorphism of MTHFR {#sec014}
-------------------------------------------------------------------------------------

Besides C677T, meta-analysis on the association between MTHFR A1298C polymorphism and NAFLD risks was also performed. [Table 2](#pone.0154337.t002){ref-type="table"} showed the genotype distribution and characteristics of MTHFR A1298C polymorphism. All the control groups of these studies were in line with HWE (All *P*\>0.05). In addition, all the case-control studies were performed in Caucasian population. We then first performed the meta-analysis between the allele frequency of MTHFR A1298C and the susceptibility to NAFLD under C vs A model. As shown in [Fig 4A](#pone.0154337.g004){ref-type="fig"}, random-effect model was used, due to the existence of high between-studies heterogeneity (I^2^ = 66% and *P* = 0.001) for meta-analysis. The data (OR = 1.53, 95% CI = 1.13\~2.07, *P* = 0.006) was obtained in C vs A comparison of MTHFR A1298C. The basically symmetric plot (z = 0.93, *P* = 0.350) did not provide the statistical evidence for publication bias ([Fig 4B](#pone.0154337.g004){ref-type="fig"}).

![Meta analysis for the association between A1298C allele frequency of MTHFR and the risks of NAFLD.\
(A) Forest plot under C vs A model; (B) Begg's funnel plot of publication biases under C vs A model.](pone.0154337.g004){#pone.0154337.g004}

Moreover, we also performed the pooled analysis for the associations between MTHFR genotype frequencies of A1298C and the susceptibility to NAFLD ([Table 5](#pone.0154337.t005){ref-type="table"}). The data of C/C vs A/A model (I^2^ = 39% and *P* = 0.09), A/C vs A/A model (I^2^ = 53% and *P* = 0.02), A/C+C/C vs A/A model (I^2^ = 63% and *P* = 0.003) was obtained and random-effect model was used. For the C/C vs A/A+A/C model, fixed-effect model was used (I^2^ = 14% and *P* = 0.31). A significantly increased NAFLD risks was observed in homozygote model (C/C vs A/A, OR = 2.81, 95% CI = 1.63\~4.85, *P* = 0.0002), dominant model (A/C+C/C vs A/A, OR = 1.60, 95% CI = 1.06\~2.41, P = 0.03) and recessive models (C/C vs A/A+A/C, OR = 2.08, 95% CI = 1.45\~3.00, *P*\<0.0001), but not heterozygote model (A/C vs A/A, OR = 1.38, 95% CI = 0.94\~2.03, *P* = 0.10). Moreover, similar results were obtained in the sensitivity meta-analyses under all genetic models ([Fig 5](#pone.0154337.g005){ref-type="fig"}). These data suggested that C/C genotype of MTHFR A1298C polymorphism is more likely to be strongly associated with the susceptibility to NAFLD in Caucasian population.

![The sensitivity meta-analyses for the association between A1298C polymorphism of MTHFR and the risks of NAFLD.](pone.0154337.g005){#pone.0154337.g005}

10.1371/journal.pone.0154337.t005

###### Pooled analysis for the association between MTHFR A1298C genotype frequencies and the risks of NAFLD.

![](pone.0154337.t005){#pone.0154337.t005g}

  Comparison                       study              case          control   Test of association   Heterogeneity   Model                                                         
  -------------------------------- ------------------ ------------- --------- --------------------- --------------- ------------------------- -------------- -------- ----------- -------
  **C/C vs A/A (homozygote)**                         **C/C**                 **C/C**                               **2.81 \[1.63, 4.85\]**   **0.0002**     **39**   **0.09**    **R**
                                   de Carvalho,2013   0             20        2                     28              0.26 \[0.01, 5.69\]                                           
                                   Franco,2013        7             81        6                     71              1.02 \[0.33, 3.20\]                                           
                                   Kasapoglu,2015     8             20        4                     44              6.67 \[1.71, 26.04\]                                          
                                                      6             10        4                     44              15.00 \[2.94, 76.56\]                                         
                                                      3             6         4                     44              10.00 \[1.49, 66.99\]                                         
                                   Orlovskiy,2015     13            66        3                     23              1.64 \[0.42, 6.35\]                                           
                                                      4             36        3                     23              0.83 \[0.17, 4.12\]                                           
                                                      9             31        3                     23              2.73 \[0.65, 11.51\]                                          
                                   Sazci,2008         10            23        33                    170             3.19 \[1.29, 7.92\]                                           
                                                      4             11        19                    92              2.20 \[0.58, 8.29\]                                           
                                                      6             12        14                    78              4.57 \[1.28, 16.29\]                                          
  **A/C vs A/A (heterozygote)**                       **A/C**                 **A/C**                               **1.38 \[0.94, 2.03\]**   **0.10**       **53**   **0.02**    **R**
                                   de Carvalho,2013   15            35        17                    43              1.15 \[0.46, 2.84\]                                           
                                   Franco,2013        53            127       63                    128             0.74 \[0.45, 1.21\]                                           
                                   Kasapoglu,2015     18            30        24                    64              2.50 \[1.03, 6.08\]                                           
                                                      8             12        24                    64              3.33 \[0.91, 12.26\]                                          
                                                      5             8         24                    64              2.78 \[0.61, 12.68\]                                          
                                   Orlovskiy,2015     34            87        17                    37              0.75 \[0.35, 1.64\]                                           
                                                      17            49        17                    37              0.63 \[0.26, 1.50\]                                           
                                                      16            38        17                    37              0.86 \[0.34, 2.13\]                                           
                                   Sazci,2008         34            47        154                   291             2.33 \[1.18, 4.59\]                                           
                                                      20            27        79                    152             2.64 \[1.05, 6.61\]                                           
                                                      14            20        75                    139             1.99 \[0.72, 5.48\]                                           
  **A/C+C/C vs A/A (dominant)**                       **A/C+C/C**             **A/C+C/C**                           **1.60 \[1.06, 2.41\]**   **0.03**       **63**   **0.003**   **R**
                                   de Carvalho,2013   15            35        19                    45              1.03 \[0.42, 2.51\]                                           
                                   Franco,2013        60            134       69                    134             0.76 \[0.47, 1.23\]                                           
                                   Kasapoglu,2015     26            38        28                    68              3.10 \[1.34, 7.15\]                                           
                                                      14            18        28                    68              5.00 \[1.49, 16.79\]                                          
                                                      8             11        28                    68              3.81 \[0.93, 15.64\]                                          
                                   Orlovskiy,2015     47            100       20                    40              0.89 \[0.43, 1.85\]                                           
                                                      21            53        20                    40              0.66 \[0.29, 1.50\]                                           
                                                      25            47        20                    40              1.14 \[0.49, 2.64\]                                           
                                   Sazci,2008         44            57        187                   324             2.48 \[1.29, 4.78\]                                           
                                                      24            31        98                    171             2.55 \[1.04, 6.25\]                                           
                                                      20            26        89                    153             2.40 \[0.91, 6.31\]                                           
  **C/C vs A/A+A/C (recessive)**                      **C/C**                 **C/C**                               **2.08 \[1.45, 3.00\]**   **\<0.0001**   **14**   **0.31**    **F**
                                   de Carvalho,2013   0             35        2                     45              0.25 \[0.01, 5.27\]                                           
                                   Franco,2013        7             134       6                     134             1.18 \[0.38, 3.60\]                                           
                                   Kasapoglu,2015     8             38        4                     68              4.27 \[1.19, 15.29\]                                          
                                                      6             18        4                     68              8.00 \[1.96, 32.68\]                                          
                                                      3             11        4                     68              6.00 \[1.13, 31.80\]                                          
                                   Orlovskiy,2015     13            100       3                     40              1.84 \[0.50, 6.85\]                                           
                                                      4             53        3                     40              1.01 \[0.21, 4.78\]                                           
                                                      9             47        3                     40              2.92 \[0.73, 11.64\]                                          
                                   Sazci,2008         10            57        33                    324             1.88 \[0.87, 4.06\]                                           
                                                      4             31        19                    171             1.19 \[0.37, 3.76\]                                           
                                                      6             26        14                    153             2.98 \[1.03, 8.64\]                                           

R: Random-effect; F:Fixed-effect.

Discussion {#sec015}
==========

Several studies have reported the potential association between the most common allelic variants of MTHFR gene (C677T and A1298C) and susceptibility to many clinical diseases, such as gastric cancer, hepatocellular carcinoma, NAFLD, neural tube defects, acute lymphoblastic leukemia and renal/heart failure \[[@pone.0154337.ref011], [@pone.0154337.ref025], [@pone.0154337.ref026], [@pone.0154337.ref038]--[@pone.0154337.ref042]\]. For example, MTHFR C677T polymorphism is found to be linked to an increased risk of neural tube defects \[[@pone.0154337.ref040]\]; MTHFR gene mutations might be conductive to renal function in Italian population \[[@pone.0154337.ref042]\]. However, the effect of MTHFR polymorphisms in the presence of NAFLD remains inconclusive in different populations \[[@pone.0154337.ref022]--[@pone.0154337.ref030]\]. For instance, C677T and A1298C polymorphisms of MTHFR gene were significantly associated with NASH risks in Turkish population \[[@pone.0154337.ref026]\]. The association of MTHFR A1298C polymorphism with NAFLD severity was also observed in Italy population \[[@pone.0154337.ref022]\]. However, both MTHFR C677T and A1298C polymorphisms were not considered as the potential genetic risk factors for the development of NAFLD in Brazilian population \[[@pone.0154337.ref029]\]. The data of Serin et al also suggested that MTHFR C677T polymorphism is unlikely to be associated with the progression of non-alcoholic fatty liver to NASH in their Turkish cohort study \[[@pone.0154337.ref025]\]. Here, a meta-analysis was first conducted to further comprehensively evaluate the genetic association, based on the data from all available population-based case-control studies.

The positive correlation between NAFLD susceptibility and two MTHFR variants (C677T and A1298C) was observed in our statistical evidence. For C677T polymorphism, an increased NAFLD risk was observed under homozygote model (T/T vs C/C) and recessive model (T/T vs C/C+C/T), but not T vs C, C/T vs C/C and C/T+T/T vs C/C models, suggesting that T/T genotype of MTHFR C677T polymorphism might have the increased risks of NAFLD in general population. Moreover, we found that a significantly increased NAFLD risk was detected in Asian population under the comparison of T vs C, T/T vs C/C, C/T vs C/C; C/T+T/T vs C/C. Similarly, the meta-analysis of A1298C polymorphism based on 11 case-control studies in Caucasian population provided the evidence that a significantly increased NAFLD risk was observed under allele model (C vs A), homozygote model (C/C vs A/A), dominant model (A/C+ C/C vs A/C) and recessive model (C/C vs A/A+A/C), but not heterozygote model (A/C vs A/A), suggesting that C/C genotype of MTHFR A1298C polymorphism might be linked to the susceptibility to NAFLD in Caucasian population.

The C677T polymorphism means the substitution of C (cytosine) to T (thymine) at nucleotide position 677, which results in the transition from alanine to valine, while A1298C polymorphism refers to the transition of A (adenine) to C (cytosine) at position 1298, which leads to an amino acid substitution from glutamic acid to alanine \[[@pone.0154337.ref008]--[@pone.0154337.ref011]\]. Folate is closely associated with the synthesis, methylation and repair of DNA, and is essential for the production or maintenance of normal cell and the inhibition of tumor cells \[[@pone.0154337.ref043]--[@pone.0154337.ref045]\]. The mutations of MTHFR gene were reported to reduce the enzyme activity of MTHFR, concentration of folate, and thus take part in the up-regulation of serum Hcy levels \[[@pone.0154337.ref006], [@pone.0154337.ref046], [@pone.0154337.ref047]\]. Kasapoglu B, et al. reported that homozygote mutations of MTHFR C677T and A1298C are positively associated with the increased levels of serum Hcy in NAFLD individuals \[[@pone.0154337.ref028]\]. Here, individuals, who carry T/T genotype in C677T and C/C genotype in A1298C polymorphism, might have high risks of NAFLD. It is possible that the two harmful homozygous mutations of MTHFR gene confer susceptibility to NAFLD via the abnormity of MTHFR enzyme activity and folate-involved DNA metabolism. Intriguingly, homozygote C/C genotype of MTHFR A1298C seems to be significantly linked to a decreased risk of liver cancer in Asian population, whereas homozygote T/T genotype of MTHFR C677T shows a reversed effect \[[@pone.0154337.ref038], [@pone.0154337.ref048], [@pone.0154337.ref049]\]. More experiments are needed to investigate the molecular mechanism on the distinct roles of MTHFR polymorphisms in the occurrence of NAFLD and hepatic carcinoma.

There are some shortages or limitations in this meta-analysis, which should be pointed out. For example, no large sample size was included in the case/control groups of meta-analysis. It is still possible that other unpublished or undetected studies are present, although we selected the eligible studies independently according to the inclusion and exclusion criteria. The potential selection bias still may affect the reliability of our findings. Different degree of heterogeneity and departure from HWE was also detected in some comparisons or case-control studies. Furthermore, it was reported that C677C/C1298C compound genotype confers increased risks of NASH in Turkish women patients \[[@pone.0154337.ref026]\]. Unfortunately, we failed to carry out the meta-analysis to investigate the potential role of MTHFR susceptibility loci combination in the susceptibility to NAFLD, due to the limitation of relevant data.

Very complicated natural history of NAFLD was existed, and multiple genetic or environmental factors contribute to the occurrence and progression of the NAFLD \[[@pone.0154337.ref050]--[@pone.0154337.ref053]\]. NAFLD has become a public health concern for its close relation with the other metabolic syndrome, hyperhomocysteinemia, obesity, hypertension, type 2 diabetes mellitus, cardiovascular disease or hepatocellular carcinoma \[[@pone.0154337.ref050]--[@pone.0154337.ref054]\]. Accumulating evidence showed the relationship between the MTHFR polymorphism and the pathogenesis of NAFLD-associated diseases \[[@pone.0154337.ref038], [@pone.0154337.ref042], [@pone.0154337.ref055]--[@pone.0154337.ref057]\]. To perform more frequent screening of functional MTHFR gene variants and other potential clinical characteristics is useful to reduce the development of the above diseases. Larger and well-designed studies and further meta-analyses based on population feature, disease status, gender, geographical location, detailed information of diet or physical activity are required to study the role of MTHFR mutation in the risks of NAFLD and NAFLD-associated diseases.

Conclusion {#sec016}
----------

All in all, this is the first meta-analysis to provide evidence that C677T and A1298C mutations of MTHFR are significantly associated with an increased risk of NAFLD. The homozygous T/T genotype of MTHFR C677T and C/C genotype of MTHFR A1298C polymorphism seem to be more susceptible to NAFLD. More case-control studies are warranted to validate the conclusion.
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